Abstract
Purpose
To review the current evidence regarding protocols and outcomes of image-guided focal therapy (FT) for prostate cancer (PCa).
Methods
A literature search of the latest published studies assessing primary FT for PCa was carried out in Medline and Cochrane library databases followed by a critical review. FT modalities, follow-up strategies, and oncological and toxicity outcomes were summarized and discussed in this review.
Results
Twenty-four studies with six different sources of energy met the inclusion criteria. A heterogeneity of patient selection, energy sources, treatment templates, and definitions of failure was found among the studies. While a third of patients may be found to have additional cancer burden over 3–5 years following FT, most patients will remain free of a radical procedure. The vast majority of patients maintain urinary continence and good erectile function after FT. Acute urinary retention is the most common complication, whilst severe complications remain rare.
Conclusion
An increasing number of prospective studies with longer follow-up have been recently published. Acceptable cancer control and low treatment toxicity after FT have been consistently reported. Follow-up imaging and routine biopsy must be encouraged post-FT. While there is no reliable PSA threshold to predict failure after FT, reporting post-FT positive biopsies and retreatment rates appear to be standard when assessing treatment efficacy.
References
Tyson MD, Koyama T, Lee D et al (2018) Effect of prostate cancer severity on functional outcomes after localized treatment: comparative effectiveness analysis of surgery and radiation study results. Eur Urol 74(1):26–33
Polascik TJ, Mouraviev V (2009) Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology 74:726–730
Baco E, Ukimura O, Rud E et al (2015) Magnetic resonance imaging—transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67(4):787–794
Tay KJ, Amin MB, Ghai S et al (2018) Surveillance after prostate focal therapy. World J Urol 37(3):397–407
Valerio M, Cerantola Y, Eggener SE et al (2017) New and established technology in focal ablation of the prostate: a systematic review. Eur Urol 71(1):17–34
Lodeizen O, de Bruin M, Eggener S et al (2019) Ablation energies for focal treatment of prostate cancer. World J Urol 37(3):409–418
Ward JF, Nakanishi H, Pisters L et al (2009) Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 104(4):490–497
Jones JS (2007) Focal or subtotal therapy for early stage prostate cancer. Curr Treat Options Oncol 8(3):165–172
Guillaumier S, Peters M, Arya M et al (2018) A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol 74(4):422–429
Rischmann P, Gelet A, Riche B et al (2017) Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients. Eur Urol 71(2):267–273
Albisinni S, Aoun F, Belluccci S et al (2017) Comparing high-intensity focal ultrasound hemiablation to robotic radical prostatectomy in the management of unilateral prostate cancer: a matched-pair analysis. J Endourol 31(1):14–19
Ganzer R, Hadaschik B, Pahernik S et al (2018) Prospective multicenter phase II study on focal therapy(hemiablation) of the prostate with high intensity focused ultrasound. J Urol 199(4):983–989
Johnston MJ, Emara A, Noureldin M et al (2019) Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-center in the United Kingdom. Urology 133:175–181
Tourinho-Barbosa RR, Sanchez-Salas R, Claros OR et al (2019) Focal therapy for localized prostate cancer with either HIFU or cryoablation: a single institution experience. J Urol. https://doi.org/10.1097/JU.0000000000000506
Mortezavi A, Krauter J, Gu A et al (2019) Extensive histological sampling following focal therapy of clinically significant prostate cancer with high intensity focused ultrasound. J Urol 202(4):717–724
Stabile A, Orczyk C, Hosking-Jervis F et al (2019) Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int 124(3):431–440
von Hardenberg J, Westhoff N, Baumunk D et al (2018) Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: a prospective evaluation. Urol Oncol 36(9):401.e1–401.e9
Schmid FA, Schindele D, Mortezavi A et al (2019) Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer. Urol Oncol. https://doi.org/10.1016/j.urolonc.2019.09.001
Tay KJ, Polascik TJ, Elshafei A et al (2017) Propensity score-matched comparison of partial to whole-gland cryotherapy for intermediate-risk prostate cancer: an analysis of the cryo on-line data registry data. J Endourol 31(6):564–571
Shah TT, Peters M, Eldred-Evans D et al (2019) Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol 76(1):98–105
Kongnyuy M, Lipsky MJ, Islam S et al (2017) Predictors of biochemical recurrence after primary focal cryosurgery (hemiablation) for localized prostate cancer: a multi-institutional analytic comparison of Phoenix and Stuttgart criteria. Urol Oncol 35(8):530.e15–530.e19
Oishi M, Gill IS, Tafuri A et al (2019) Hemigland cryoablation of localized low, intermediate and high risk prostate cancer: oncologic and functional outcomes at 5 years. J Urol 202(6):1188–1198
Azzouzi A, Vincendeau S, Barret E et al (2017) Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 18(2):181–191
Noweski A, Roosen A, Lebdai S et al (2019) Medium-term follow-up of vascular-targeted photodynamic therapy of localized prostate cancer using TOOKAD soluble WST-11 (Phase II trials). Eur Urol Focus 5(6):1022–1028
Rodriguez-Rivera JA, Rodriguez-Lay R, Zegarra-Montes L et al (2018) Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study. Actas Urol Esp 42(10):632–638
Blazevski A, Scheltema MJ, Yuen B et al (2019) Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2019.04.008
Valerio M, Dickinson L, Ali A et al (2017) Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer. J Urol 197(3):647–654
Collettini F, Enders J, Stephan C et al (2019) Image-guided irreversible electroporation of localized prostate cancer: functional and oncologic outcomes. Radiology 292(1):250–257
Chao B, Llukani E, Lepor H (2018) Two-year outcomes following focal laser ablation of localized prostate cancer. Eur Urol Oncol 1(2):129–133
Walser E, Nance A, Ynalvez L et al (2019) Focal laser ablation of prostate cancer: results in 120 patients with low- to intermediate-risk disease. J Vasc Interv Radiol 30(3):401–409
Peters M, van Son MJ, Moerland MA et al (2019) MRI-guided ultrafocal HDR brachytherapy for localized prostate cancer: median 4-year results of a feasibility study. Int J Radiat Oncol Biol Phys 104(5):1045–1053
Graff P, Portalez D, Lusque A et al (2018) IDEAL 2a phase II study of ultrafocal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 102(4):903–911
Tay KJ, Scheltema MJ, Ahmed HU (2017) Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis 20(3):294–299
Scheltema MJ, Tay KJ, Postema AW et al (2017) Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol 35(5):695–701
Ahdoot M, Wilbur AR, Reese SE et al (2020) MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med 382(10):917–928
Kennedy JE, Ter Haar GR, Cranston D (2003) High intensity focused ultrasound: surgery of the future? Br J Radiol 76(909):590–599
Nguyen HD, Allen BJ, Pow-Sang JM (2013) Focal cryotherapy in the treatment of localized prostate cancer. Cancer Control 20(3):177–180
Azzouzi A, Barret E, Moore CM et al (2013) TOOKAD((R)) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 112(6):766–774
Al-Sakere B, André F, Bernat C et al (2007) Tumor ablation with irreversible electroporation. PLoS ONE 2(11):e1135
Lepor H, Llukani E, Sperling D et al (2015) Complications, recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer. Eur Urol 68(6):924–926
Cosset JM, Cathelineau X, Wakil G et al (2013) Focal brachytherapy for selected low-risk prostate cancers: a pilot study. Brachytherapy 12(4):331–337
Sivaraman A, Barret E (2016) Focal therapy for prostate cancer: an “À la Carte” approach. Eur Urol 69(6):973–975
Ashrafi AN, Nassiri N, Gill IS et al (2018) Contrast-enhanced transrectal ultrasound in focal therapy for prostate cancer. Curr Urol Rep 19(10):87
Claros OR, Tourinho-Barbosa RR, Carneiro A (2019) HIFU focal therapy for prostate cancer using intraoperatory contrast enhanced ultrasound. Arch Esp Urol 78(8):825–830
Kongnyuy M, Islam S, Mbah AK et al (2018) PSA kinetics following primary focal cryotherapy (hemiablation) in organ-confined prostate cancer patients. World J Urol 36(2):209–213
Tourinho-Barbosa RR, de la Rosette J, Sanchez-Salas R (2018) Prostate cancer multifocality, the index lesion, and the microenvironment. Curr Opin Urol 28(6):499–505
Kadono Y, Machioka K, Nakashima K et al (2017) Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism. BJU Int 120(2):293–299
Author information
Authors and Affiliations
Contributions
RRT-B: literature search/data analysis/manuscript writing. BJW: critical revision. ALA: literature search/data analysis/critical revision. BN: critical revision/manuscript writing. TS: literature search/critical revision. SG: critical revision. TJP: data analysis/manuscript writing/critical revision
Corresponding author
Ethics declarations
Conflict of interest
The authors declared no conflicts of interest.
Research involving human participants and/or animals
No human subjects or animals were involved in this study.
Informed consent
Due to the nature of this article, acquisition of informed consent is not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tourinho-Barbosa, R.R., Wood, B.J., Abreu, A.L. et al. Current state of image-guided focal therapy for prostate cancer. World J Urol 39, 701–717 (2021). https://doi.org/10.1007/s00345-020-03254-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-020-03254-4